ADVERTISEMENT
Poster
2757112
Real-world Survey of Clinical Experience using Dexmedetomidine Sublingual Film for Acute Agitation in over 200 Adults with Schizophrenia or Bipolar Disorder
Abstract: Purpose: Agitation treatment in patients with schizophrenia or bipolar disorder is challenging. Alpha-2 agonist, IGALMI™ DSF (dexmedetomidine sublingual film) reduces norepinephrine. Real-world survey data from over 200 DSF-treated patients reported in the absence of existing publications.
Methods: Consolidated results from 2 surveys (one year apart) with 35 total questions sent to 80 clinicians from 30 institutions.
Results: Twenty-two respondents treating over 200 patients with DSF in multiple clinical settings. Most important feature was targeted mechanism of action. Starting doses equally 180-mcg and 120-mcg with 33% multiple times weekly. Impaired patients treated, and most self-administered. Only 20% used agitation protocols and 10% severity assessment tools. No additional patient monitoring required by 92% of respondents.
Patient response time
Sign Up
Psych Congress Network Newsletter
